CERo Therapeutics Holdings, Inc. (CERO)
Develops engineered T cells to fight cancer by training patient immune cells to kill tumor cells
$0.01+0.28%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-99.8%
The outlook
CERO is trading near its 52-week low at $0.0124, well below both its 50- and 200-day moving averages. Analyst coverage is thin, and the stock carries a bearish sentiment score. The trailing P/E is not meaningful given the company's current financial position.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range0% of the way from its 52-week low to high
Market cap
$559,393
52-wk high
$8.90
52-wk low
$0.01
50-day avg
$0.01
200-day avg
$0.25
Trailing P/E
0.0